Amgen Inc. is an independent biotechnology drug company that researches, develops, manufactures and markets drugs for serious diseases. The company is active in 100 countries and focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology (kidney disease) and inflammation.
Innovation activities are focused on the development of novel drugs based on advanced cell and molecular biology. Research into the fundamental biological mechanisms of disease is the key feature of Amgen’s research efforts. The treatment of millions of critically ill patients worldwide depends on the safe and reliable production of biological drugs administered by injection or intravenously. Amgen is the world leader in the manufacture and delivery of biologicals to patients.
Amgen’s subsidiary deCODE Genetics is a global leader in human genetics. The company focuses on the analysis of genetic risk factors of common diseases. The knowledge gained there is used for cardiovascular or cancer therapies.
The company’s goal is to continue to identify knowledgeable biological processes, develop first-class therapies and remain a pioneer in biotechnology in the future.